MedTrace Logo

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

NCT05513742 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-05-06

No results posted yet for this study

Summary

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.

A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Conditions

Interventions

DRUG

CTX-009

IV infusion administered on day 1 and 15 of every 28-day cycle

Sponsors & Collaborators

  • Compass Therapeutics

    lead INDUSTRY

Principal Investigators

  • Minori Rosales, MD, PhD · Compass Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-08
Primary Completion
2025-05-15
Completion
2025-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05513742 on ClinicalTrials.gov